Longevity Protocol with Fatty Liver Disease

Why NAFLD Is a Longevity Emergency

Non-alcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, a name that reflects what drives it.² In a global meta-analysis it affected about 30 percent of adults, rising from about 25 percent in 1990–2006 to 38 percent in 2016–2019.¹ It is often dismissed as benign. It is not: a fatty liver becomes insulin resistant, overproduces triglyceride-rich lipoproteins and contributes to systemic inflammation.

Cardiovascular disease, not liver failure, is a leading cause of death in people with fatty liver. In a meta-analysis, fatty liver was associated with a 45 percent higher risk of fatal or non-fatal cardiovascular events, rising to 2.5 times with advanced fibrosis, independent of age, sex, adiposity, diabetes and other common risk factors.³

The progression runs from fat accumulation (steatosis) to inflammation (steatohepatitis, now called MASH), fibrosis, cirrhosis, and liver failure or liver cancer. Only a minority progress, but with this prevalence the absolute numbers are large.

The critical longevity insight: fatty liver is reversible before cirrhosis. In a study of lifestyle-driven weight loss, everyone who lost at least 10 percent of their body weight improved; 90 percent had resolution of steatohepatitis and 45 percent had regression of fibrosis.⁴

Exercise: The Liver's Best Medicine

Exercise reduces liver fat even without much weight loss. In a randomized trial, several aerobic exercise regimens reduced liver fat and visceral fat by a small amount without clinically significant weight loss.⁵ In people with type 2 diabetes, even low-volume interval training reduced liver fat compared with no exercise.⁶

Aerobic exercise (150–300 min/week) — Walking, cycling or swimming at a conversational pace. Both moderate continuous training and intervals reduce liver fat, so pick what you will sustain.^5,6

Resistance training (2–3x/week) — Builds muscle, the main site of glucose disposal, and supports insulin sensitivity alongside aerobic work.

Reduce sedentary time. Long, unbroken sitting is linked with more liver fat in observational studies. Break it up with short movement breaks every 30 to 60 minutes; walking meetings and post-meal walks help.

Nutrition: Reversing the Metabolic Driver

Cut sugar-sweetened beverages. Fructose is largely metabolized in the liver, where excess promotes fat production. Juice, soda, sweetened coffee drinks and sports drinks are the easiest place to start.

Mediterranean-style eating — Olive oil, fish, vegetables, legumes and nuts support cardiometabolic health and are commonly recommended for fatty liver. Skip the wine: alcohol adds to the liver's load.

Adequate protein — Supports muscle during weight loss and improves satiety; spread it across meals.

Weight loss of 5–10% — If you carry excess weight, the more you lose, the more the liver improves: the degree of weight loss was independently linked to improvement in every histologic feature, and losing 10 percent or more resolved steatohepatitis in 90 percent of people.⁴ Any sustainable approach to a calorie deficit works.

Time-restricted eating — Fine if it helps you eat less, but in a 12-month randomized trial in adults with obesity and fatty liver, it added no benefit for liver fat over simple daily calorie restriction.⁷ Calories matter more than the clock.

Testing Beyond Standard Liver Enzymes

ALT and AST are insensitive. Normal liver enzymes do not rule out fatty liver, so imaging or non-invasive scores are needed when risk factors are present. GGT adds context.

Liver ultrasound — First-line imaging for NAFLD detection. Widely available and inexpensive. Detects moderate-severe steatosis but may miss mild disease.

FibroScan (transient elastography) — Quantifies liver fat (CAP score) and stiffness, a marker of fibrosis, in about 10 minutes without a needle. How often to repeat it depends on your stage.

Metabolic panel — Fasting insulin, HOMA-IR, ApoB, triglycerides, hs-CRP. NAFLD is a metabolic disease — track the metabolic markers that drive it and the cardiovascular risk it amplifies.

FIB-4 score — A simple calculation from age, ALT, AST, and platelets that screens for advanced fibrosis. FIB-4 under 1.3 effectively rules out advanced fibrosis. Available online — calculate yours.

Supplements and Medications for NAFLD

Vitamin E (800 IU/day) — In the PIVENS trial in adults with steatohepatitis but without diabetes, 800 IU a day improved liver histology in 43 percent versus 19 percent on placebo over 96 weeks.⁸ But in the SELECT trial, vitamin E supplements raised prostate cancer risk in men (hazard ratio 1.17),⁹ so use it only under medical supervision.

Omega-3 fatty acids — Lower blood triglycerides, but they have not been shown to resolve steatohepatitis.

Berberine — Small trials suggest improvements in liver fat and enzymes, but study quality is mixed, and it interacts with several drugs. Check with your doctor first.

Resmetirom (Rezdiffra) — The first drug approved in the US for steatohepatitis with moderate-to-advanced fibrosis. In its phase 3 trial, steatohepatitis resolved in 25.9 to 29.9 percent of patients versus 9.7 percent on placebo, and fibrosis improved by at least one stage in about a quarter.¹⁰

GLP-1 agonists (semaglutide) — In a phase 3 trial in steatohepatitis with fibrosis, semaglutide resolved steatohepatitis in 62.9 percent of patients versus 34.3 percent on placebo.¹¹ Especially relevant when obesity or diabetes is also present.

Coffee — In a meta-analysis of observational studies, coffee drinkers had a 23 percent lower risk of fatty liver and a lower risk of liver fibrosis.¹² Drink it unsweetened.